Clinical objective:
Target active pathological or functional skin disorders.

This phase focuses on direct intervention on visible and underlying skin alterations such as structural damage, dyschromias, inflammatory conditions, acne, scars, or loss of dermal signaling.

Role of products:
Active correction only.

Clinical objective:
Consolidate results and restore skin functional balance.

This phase aims to normalize skin physiology, reinforce the barrier function, regulate inflammation, control pigmentation pathways, and reduce the risk of relapse.

Role of products:
Functional normalization and result consolidation.

Clinical objective:
Maintain results over time and prevent recurrence.

This phase ensures long-term skin balance, preserves anti-aging benefits, supports controlled stimulation, and integrates home-care continuity.

Role of products:
Protection, support, and prevention.

Active metabolic correction protocols for structural and functional skin modulation.

Progressive skin rejuvenation strategies combining correction, stabilization, and long-term maintenance.

Structured approaches to melasma and hyperchromias based on correction, stabilization, and recurrence control.